Midatech inks evaluation agreement with Asian pharma outfit
20th Dec 2018 10:12
(Sharecast News) - Pharmaceutical research and development outfit Midatech has inked an agreement with an unnamed company to evaluate its Q-Sphera drug delivery platform.
Read moreMidatech Pharma 'on track' for first half
25th Jul 2018 10:15
(Sharecast News) - Cancer-focused pharmaceutical company Midatech Pharma has remained "on track" to deliver financial results for the first half of the calendar year in line with market expectations, and was still exploring options about how to meet its cash flow needs.
Read moreMidatech Pharma receives upfront access fee
22nd Nov 2016 13:29
(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop
Read moreMidatech Pharma chooses MTR104 for liver cancer treatment
15th Nov 2016 12:04
(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l
Read moreMidatech Pharma's revenues increases due to US sales
2nd Sep 2016 12:07
(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s
Read moreMidatech particle technology to be used in vaccines
4th Jan 2016 14:18
(ShareCast News) - Midatech Pharma's proprietary technology received a boost on Monday, with the news it had signed a licensing agreement with a private British biotechnology company. The AIM-listed pharmaceutical company - focused on products in oncology and other therapeutic areas - reported it ha
Read more